FLUTCORE
Development of a universal influenza vaccine based on tandem core technology
| Coordinatore | UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Totale costo | 5˙063˙520 € |
| EC contributo | 3˙872˙919 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2013-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-09-01 - 2017-03-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | coordinator | 838˙259.00 |
| 2 |
IQUR LIMITED
Organization address
address: ROYAL COLLEGE STREET 2 LONDON contact info |
UK (LONDON) | participant | 966˙822.00 |
| 3 |
3P BIOPHARMACEUTICALS SL
Organization address
address: CALLE MOCHOLI 2 POLIGONO MOCHOLI contact info |
ES (NOAIN NAVARRA) | participant | 754˙961.00 |
| 4 |
Luxembourg Institute of Health
Organization address
address: Val Fleuri 84 contact info |
LU (LUXEMBOURG) | participant | 664˙443.00 |
| 5 |
LATVIJAS BIOMEDICINAS PETIJUMU UN STUDIJU CENTRS
Organization address
address: RATSUPITES IELA 1 contact info |
LV (RIGA) | participant | 300˙030.00 |
| 6 |
UNIVERSITY OF LEEDS
Organization address
address: WOODHOUSE LANE contact info |
UK (LEEDS) | participant | 266˙984.00 |
| 7 |
INSTITUT CATALA DE LA SALUT
Organization address
address: GRAN VIA DE LES CORTS CATALANES 587 contact info |
ES (BARCELONA) | participant | 81˙420.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'FLUTCORE will develop a novel universal influenza A virus (IAV) vaccine based on the tandem core vaccine platform. Recent influenza pandemics have emphasized the urgent need for better vaccines that are reactive with multiple IAV subtypes and that are no longer dependent on intimate knowledge of the prevalent virus. We propose to replace the existing seasonal IAV vaccine with a virus like particle (VLP) carrying several invariant “universal” influenza antigens. Previous attempts to use these targets have failed due to the poor antigen expression and immunogenicity. The highly immunogenic tandem core system overcomes this limitation. Specifically, we propose to develop a VLP carrying two or more invariant influenza antigens, express these in yeast and then examine immunogenicity in mice. The vaccine will be further tested in the rigorous ferret system before being scaled up for manufacture. An optimal clone will then be transferred to an accredited contract manufacturer for production. A phase I clinical trial will be carried out once pre-clinical toxicology has been successfully completed. Our consortium will examine the immune responses in both animals and humans thoroughly to ensure that the vaccine candidate chosen can produce a protective IAV immune response in all individuals. To achieve these objectives, our proposal builds upon the complementary expertise of seven high-performing partners representing four European countries, with world leadership in HBV core biology, immunological analysis, commercial manufacture and influenza clinical trials, making our consortium ideally positioned to develop the vaccine and to take it from bench to bedside. The leading role of SMEs in the consortium will ensure that the technology developed by FLUTCORE will generate highly marketable products, offering both improved patient protection and long-term cost savings for health care in Europe once annual influenza vaccines are replaced.'